RepliCel Life Sciences
OTCQB : NCSLF

RepliCel Life Sciences

May 04, 2011 17:16 ET

RepliCel Life Sciences Launches New Corporate Website

VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 4, 2011) - To properly reflect the company's business focus, Newcastle Resources Ltd. is now doing business under the name RepliCel Life Sciences (the "Company" or "RepliCel") (OTCQB:NCSLF). RepliCel is developing a cell-based procedure for the treatment of androgenetic alopecia, also known as pattern baldness and general hair loss in men and women. The company intends to formally change its legal name in due course.

RepliCel is pleased to announce the launch of its new corporate website located at www.replicel.com. The new website provides visitors with a comprehensive source of information on the company's hair replacement technology and first-in-human clinical trial. On the home page, you can view a 3-D video animation explaining the mechanics and science behind the Replicel™ procedure. Stakeholders can also learn about the history of the company and its medical and scientific team. We encourage viewers to fill out the information request form to stay up-to-date on all corporate initiatives.

About RepliCel Life Sciences

RepliCel Life Sciences has developed RepliCel™, a natural hair cell replication technology that has the potential to become the world's first, minimally invasive solution for androgenetic alopecia and general hair loss in both men and women. RepliCel™ is based on autologous cell implantation technology that replicates a patient's hair cells from their own healthy hair follicles and, when reintroduced into areas of hair loss, the company hopes to initiate natural hair regeneration. Patents for the technology have been issued by the European Union and Australia and are pending in other major international jurisdictions. The RepliCel™ procedure has been developed over the past nine years by the Company's recognized research scientists and medical experts – specialists in the fields of hair growth, hair biology and dermatology.

On behalf of the Board of Directors,

David Hall, CEO & President

Notice Regarding Forward Looking Statements

This press release contains projections and forward-looking statements, as that term is defined under applicable securities laws. Statements in this press release, which are not purely historical, are forward-looking statements and can include, without limitation, statements based on current expectations involving a number of risks and uncertainties and which are not guarantees of future performance of the Company such as the statement that the Replicel hair cell replication technology has the potential to become the world's first, minimally invasive solution for androgenetic alopecia and general hair loss in both men and women. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including any adverse occurrence with respect to the patenting ortesting of the Replicelhair cell replication technology. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Although the Company believes that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance those beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2010 and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact Information